Literature DB >> 27782968

Dolutegravir in breast milk and maternal and infant plasma during breastfeeding.

Robin Kobbe1, Stein Schalkwijk, Gabor Dunay, Johanna M Eberhard, Ulf Schulze-Sturm, Bettina Hollwitz, Olaf Degen, Marga Teulen, Angela Colbers, David Burger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27782968     DOI： 10.1097/QAD.0000000000001259

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation.

Authors:  Joseph Piscitelli; Mina Nikanjam; Brookie M Best; Edward Acosta; Mark Mirochnick; Diana F Clarke; Edmund V Capparelli; Jeremiah D Momper
Journal:  J Acquir Immune Defic Syndr       Date:  2022-01-01       Impact factor: 3.771

2.  Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

Authors:  Joshua Gini; Sujan Dilly Penchala; Alieu Amara; Elizabeth Challenger; Deirdre Egan; Catriona Waitt; Mohammed Lamorde; Catherine Orrell; Landon Myer; Saye Khoo; Laura J Else
Journal:  Bioanalysis       Date:  2018-11-19       Impact factor: 2.681

3.  Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.

Authors:  Andrew Hill; Polly Clayden; Claire Thorne; Rachel Christie; Rebecca Zash
Journal:  J Virus Erad       Date:  2018-04-01

4.  Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).

Authors:  Catriona Waitt; Catherine Orrell; Stephen Walimbwa; Yashna Singh; Kenneth Kintu; Bryony Simmons; Julian Kaboggoza; Mary Sihlangu; Julie-Anne Coombs; Thoko Malaba; Josaphat Byamugisha; Alieu Amara; Joshua Gini; Laura Else; Christie Heiburg; Eva Maria Hodel; Helen Reynolds; Ushma Mehta; Pauline Byakika-Kibwika; Andrew Hill; Landon Myer; Mohammed Lamorde; Saye Khoo
Journal:  PLoS Med       Date:  2019-09-20       Impact factor: 11.069

5.  Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.

Authors:  Aditya N Bade; JoEllyn M McMillan; Yutong Liu; Benson J Edagwa; Howard E Gendelman
Journal:  Mol Neurobiol       Date:  2021-08-14       Impact factor: 5.590
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.